Cargando…

Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression

Cisplatin resistance is a main clinical problem of lung cancer therapy. Gambogic acid (GA) could prohibit the proliferation of a variety of human cancer cells. However, the effects of GA on cisplatin-resistant lung cancer are still unclear. The objective of the present study was to find out the anti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Wendian, Zhou, Hechao, Yu, Ying, Li, Jingjing, Li, Haiwen, Jiang, Danxian, Chen, Zihong, Yang, Donghong, Xu, Zumin, Yu, Zhonghua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4898431/ https://www.ncbi.nlm.nih.gov/pubmed/27330316 http://dx.doi.org/10.2147/OTT.S100936

Ejemplares similares

Niclosamide enhances the antitumor effects of radiation by inhibiting the hypoxia-inducible factor-1α/vascular endothelial growth factor signaling pathway in human lung cancer cells
por: Xiang, Mei, et al.
Publicado: (2017)

Niclosamide enhances the cytotoxic effect of cisplatin in cisplatin-resistant human lung cancer cells via suppression of lung resistance-related protein and c-myc
por: Zuo, Yufang, et al.
Publicado: (2018)

Niclosamide sensitizes nasopharyngeal carcinoma to radiation by downregulating Ku70/80 expression
por: Li, Jingjing, et al.
Publicado: (2018)

Emodin Augments Cisplatin Cytotoxicity in Platinum-Resistant Ovarian Cancer Cells via ROS-Dependent MRP1 Downregulation
por: Ma, Jun, et al.
Publicado: (2014)

Emodin enhances cisplatin-induced cytotoxicity in human bladder cancer cells through ROS elevation and MRP1 downregulation
por: Li, Xinxing, et al.
Publicado: (2016)

Antitumor activity of gambogic acid on NCI-H1993 xenografts via MET signaling pathway downregulation
por: LI, DONGLEI, et al.
Publicado: (2015)

Antitumor activity of gambogic acid on NCI-H1993 xenografts via MET signaling pathway downregulation
por: Li, Donglei, et al.
Publicado: (2021)

Durable response of tislelizumab plus cisplatin, nab-paclitaxel followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A case report
por: Tang, Haifeng, et al.
Publicado: (2023)

Structural Optimization and Improving Antitumor Potential of Moreollic Acid from Gamboge
por: Cheng, Li-Zhi, et al.
Publicado: (2022)

Combination therapy of cisplatin with cilastatin enables an increased dose of cisplatin, enhancing its antitumor effect by suppression of nephrotoxicity
por: Arita, Masashi, et al.
Publicado: (2021)

Biocompatible Nanoparticles as a Platform for Enhancing Antitumor Efficacy of Cisplatin–Tetradrine Combination
por: Liu, Fangcen, et al.
Publicado: (2021)

Synergistic antitumor effects of combined deguelin and cisplatin treatment in gastric cancer cells
por: LI, ZHENGGUANG, et al.
Publicado: (2014)

Synergistic antitumor effect of brusatol combined with cisplatin on colorectal cancer cells
por: Chen, Hai-Ming, et al.
Publicado: (2018)

Natural killer cells strengthen antitumor activity of cisplatin by immunomodulation and ameliorate cisplatin-induced side effects
por: Wang, Zhu, et al.
Publicado: (2023)

Enhanced antitumor efficacy of cisplatin in combination with HemoHIM in tumor-bearing mice
por: Park, Hae-Ran, et al.
Publicado: (2009)

Antitumor effect of WEE1 blockade as monotherapy or in combination with cisplatin in urothelial cancer
por: Murakami, Kaoru, et al.
Publicado: (2021)

Istradefylline protects from cisplatin-induced nephrotoxicity and peripheral neuropathy while preserving cisplatin antitumor effects
por: Dewaeles, Edmone, et al.
Publicado: (2022)

MEK inhibition induced downregulation of MRP1 and MRP3 expression in experimental hepatocellular carcinoma
por: Lin, Shibo, et al.
Publicado: (2013)

Enhanced antitumor activity by combining an adenovirus harboring ING4 with cisplatin for hepatocarcinoma cells
por: Xie, Y, et al.
Publicado: (2011)

A Gamboge Case
por: Biegler, J. A.
Publicado: (1887)

Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer
por: Sun, Si, et al.
Publicado: (2014)

Combination therapy with cisplatin and nifedipine induces apoptosis in cisplatin-sensitive and cisplatin-resistant human glioblastoma cells.
por: Kondo, S., et al.
Publicado: (1995)

Mechanism of the formation of DNA–protein cross-links by antitumor cisplatin
por: Chválová, Kateřina, et al.
Publicado: (2007)

Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling
por: Wang, L-H, et al.
Publicado: (2014)

Synergistic antitumor effect of the combination of a dual cancer-specific oncolytic adenovirus and cisplatin on lung cancer cells
por: Jin, Jing, et al.
Publicado: (2018)

Nuclear Targeted Peptide Combined With Gambogic Acid for Synergistic Treatment of Breast Cancer
por: Dang, Wenli, et al.
Publicado: (2022)

Mitochondrial APE1 promotes cisplatin resistance by downregulating ROS in osteosarcoma
por: Liu, Yufeng, et al.
Publicado: (2020)

Improving aqueous solubility and antitumor effects by nanosized gambogic acid-mPEG(2000) micelles
por: Cai, Lulu, et al.
Publicado: (2013)

Case report of chemoradiotherapy combined with immunotherapy for liver metastasis and lymph node metastases in the head of the pancreas of nasopharyngeal carcinoma
por: Zhang, Jingtong, et al.
Publicado: (2022)

PD‐0332991 combined with cisplatin inhibits nonsmall cell lung cancer and reversal of cisplatin resistance
por: Liu, Minghui, et al.
Publicado: (2021)

Detoxifying Antitumoral Drugs via Nanoconjugation: The Case of Gold Nanoparticles and Cisplatin
por: Comenge, Joan, et al.
Publicado: (2012)

Antitumor Activity of Thermosensitive Hydrogels Packaging Gambogic Acid Nanoparticles and Tumor-Penetrating Peptide iRGD Against Gastric Cancer
por: Zhang, Dinghu, et al.
Publicado: (2020)

The synergistic antitumor effect of cinobufagin and cisplatin in human osteosarcoma cell line in vitro and in vivo
por: Dai, Guo, et al.
Publicado: (2017)

Luteolin sensitizes the antitumor effect of cisplatin in drug-resistant ovarian cancer via induction of apoptosis and inhibition of cell migration and invasion
por: Wang, Haixia, et al.
Publicado: (2018)

ECRG2 enhances the anti-cancer effects of cisplatin in cisplatin-resistant esophageal cancer cells via upregulation of p53 and downregulation of PCNA
por: Hou, Xin-Fang, et al.
Publicado: (2017)

Inhibiting WEE1 Augments the Antitumor Efficacy of Cisplatin in Urothelial Carcinoma by Enhancing the DNA Damage Process
por: Su, Yu-Li, et al.
Publicado: (2023)

Gambogic Acid Induces Pyroptosis of Colorectal Cancer Cells through the GSDME-Dependent Pathway and Elicits an Antitumor Immune Response
por: Xu, Hanjie, et al.
Publicado: (2022)

Renin-angiotensin system inhibitors combined with cisplatin exacerbate cisplatin-induced nephrotoxicity in mice
por: Tsuji, Takumi, et al.
Publicado: (2022)

Inhibition of Autophagy Potentiated the Antitumor Effect of Nedaplatin in Cisplatin-Resistant Nasopharyngeal Carcinoma Cells
por: Liu, Zhongyu, et al.
Publicado: (2015)

Gambogic acid-loaded biomimetic nanoparticles in colorectal cancer treatment
por: Zhang, Zhen, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_opddea46epeoj66bnhh9ipd6oe